poisar

Stocks · News reference

Autolus Therapeutics FY2026 AUCATZYL net product revenue expected to be more than $150.000M

BenzingaBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. BenzingaEarnings Transcripts

    Autolus Therapeutics Q3 2026 Earnings Call Transcript

    Autolus Therapeutics (NASDAQ:AUTL) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga

  2. SEC EDGARSEC EDGAR

    8-K filing — Autolus Therapeutics plc (AUTL)

    Filed: 2026-11-10 AccNo: 0001730463-26-000141 Size: 4 MB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits